Recall of Ampicillin and Sulbactam for Injection USP, 1.5 g/vial by Auromedics: Presence of glass particles

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: AuroMedics Pharma is voluntarily recalling one lot of Ampicillin and Sulbactam for Injection USP, 1.5 g in a Single-Dose vial (equivalent to 1 g ampicillin as the sodium salt plus 0.5 g Sulbactam as the sodium salt), to the hospital level. Lot AFO l 17001-A, Expiry date Dec 2018 has been found to contain glass particles.

The affected Ampicillin and Sulbactam for Injection lot is packaged in a carton containing 10 vials, NDC: 55150-116-20. The product can be identified as a ‘clear vial stoppered with grey rubber stopper and sealed with aluminum seals having a Royal Blue color polypropylene disc'. AuroMedics shipped the entire lot to wholesalers and/or hospitals nationwide on February 9, 2017.

The administration of a glass particulate, if present in an intravenous drug, may result in local irritation or swelling in response to the foreign material. More serious potential outcomes would include blockage and clotting in blood vessels, which may be life-threatening.

BACKGROUND: The product Ampicillin and Sulbactam for Injection is used for treatment of infections due to susceptible strains of designated microorganism in skin and skin structure infections, intra­abdominal infections and gynecological infections in adults and for in treatment of skin and skin structure infection in pediatric patient one year and older.

RECOMMENDATION: AuroMedics Pharma LLC is notifying...

Recommended for you

  • MedWatch Drug Updates
  • 1 comment

FDA Safety Alert - Becton-Dickinson replaced problematic rubber stoppers in its syringes

  • MedWatch Drug Updates
  • 1 comment

Anaphylaxis and other serious hypersensitivity reactions reported with use of Varubi (rolapitant) injectable emulsion

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Reprocessed Agilis Steerable Introducer Sheath by Sterilmed: Improper seal of sheath hub

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Certitude Delivery System by Edwards Lifesciences due to a mold overflow defect

  • MedWatch Drug Updates
  • 1 comment

Recall of Ampicillin and Sulbactam for Injection USP, 1.5 g/vial by Auromedics: Presence of glass particles

  • MedWatch Drug Updates
  • 1 comment

Recall of Clopidogrel Tablets, USP 75 mg by International Laboratories due to mislabeling

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Defibrillation Electrodes by Physio-Control: Artwork shows incorrect placement instruction for infants

  • MedWatch Drug Updates
  • 1 comment

Recall of Compounded Sterile Products by PharMEDium Services due to lack of sterility assurance

  • MedWatch Drug Updates
  • 1 comment

Recall of Linezolid Injection 600mg/300mL flexible bags by AuroMedics Pharma: Presence of particulate matter

  • MedWatch Drug Updates
  • 1 comment

Recall of Riomet (Metformin Hydrochloride Oral Solution) by Sun Pharmaceutical: Presence of microbial contamination

  • MedWatch Drug Updates
  • 1 comment

Long-acting beta agonists and inhaled corticosteroids: FDA removed boxed warning about asthma-related death from labels

  • MedWatch Drug Updates
  • no comment

Recall of Pantoprazole Sodium Injection 40 mg per vial by AuroMedics Pharma: Presence of glass particles

  • MedWatch Drug Updates
  • 1 comment

FDA warning: Gadolinium retention in patients body after receiving gadolinium-based contrast agents (GBCAs)

  • MedWatch Drug Updates
  • 1 comment

FDA update: Type III endoleaks associated with the use of endovascular graft systems

  • MedWatch Drug Updates
  • 1 comment

FDA update: High risk of mortality and neurological adverse events when using SynCardia's TAH-t C2 Driver System

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Bridge Occlusion Balloon Catheter Model 590-001 by Spectranetics: Blocked guidewire lumen

  • MedWatch Drug Updates
  • 1 comment

Recall of pharmacist choice alcohol prep pads by simple diagnostics due to quality concerns.

  • MedWatch Drug Updates
  • 1 comment

Fading print on label of AlbuRx 25, Albumin (Human) 25% solution

  • FDA Drug Updates
  • 1 comment

FDA approved Mvasi (bevacizumab-awwb) for the treatment of cancer

  • FDA Drug Updates
  • 1 comment

FDA approved Aliqopa (copanlisib) for the treatment of relapsed follicular lymphoma

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Intra-Aortic Balloon Pump by Datascope/MAQUET- False blood detection alarm and ingress of fluid into the pump

  • MedWatch Drug Updates
  • 1 comment

FDA recommends separate dosing for Kayexalate (sodium polystyrene sulfonate) from all other oral drugs

  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Biotin (Vitamin B7) interferes with certain lab tests

  • MedWatch Drug Updates
  • 1 comment

FDA statement on risks of unapproved use of Keytruda (pembrolizumab) for treatment of multiple myeloma

  • MedWatch Drug Updates
  • 1 comment

Recall of Piyanping Anti-Itch Lotion by Lucky Mart Inc.: Contain wrong active pharmaceutical ingredient

  • MedWatch Drug Updates
  • 1 comment

FDA investigated life-threatening adverse events associated with Limbrel Capsules by Primus Pharmaceuticals

  • FDA Drug Updates
  • 1 comment

FDA approves Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia

  • MedWatch Drug Updates
  • 1 comment

Recall of Diphenoxylate Hydrochloride and Atropine Sulfate by Greenstone: Sub-potent or super-potent product

  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Increased risk of heart-related death with febuxostat (Uloric)

  • MedWatch Drug Updates
  • no comment

Recall of Nexterone (amiodarone HCl) 150 mg/100 mL premixed injection by Baxter- Presence of particulate matter